spacer
home > ebr > summer 2017 > acting up
PUBLICATIONS
European Biopharmaceutical Review

Acting Up

On January 4, 1983, President Reagan signed the Orphan Drug Act (ODA) into law with the goal of providing financial and marketing incentives so that private pharmaceutical companies would develop more therapeutics for rare diseases. The benefits offered by the ODA include seven years of marketing exclusivity upon approval, tax credits worth 50% of the cost of human clinical trials and federal research grants to fund the development of orphan drugs.

Today, critics question whether the ODA is being used appropriately by firms. Most of this discussion is centred around the ‘orphan subset’ – a subset of a relatively common disease that a narrowly-targeted therapy might be developed for to qualify as an orphan drug and reap the ODA’s protections and benefits. In February 2017, Senator Chuck Grassley opened an inquiry into potential abuses of ODA by drug sponsor; this inquiry is likely to investigate the practice of ‘salami-slicing’ and how this may contribute to high prices of orphan drugs.

Salami-Slicing


This practice is defined as “artificially subdividing diseases to create subgroups of patients that fall under the orphan drug prevalence threshold”.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Matthew Weinberg is Chief Executive Officer at The Weinberg Group. He guides all strategic issues with management client efforts, emphasising the provision of tactical and operational assistance to technically-oriented entities in areas including R&D, regulatory affairs and quality assurance. Matthew’s assignments have involved development of new products, testimony of the management and economics of scientific enterprises, contract issues and product advancement.

Emily Krulewitz is a Consultant at The Weinberg Group. Her work involves issues related to the development and regulation of therapeutics, medical devices, tobacco products and foods. Emily has experience in the preparation, coordination and compilation of regulatory submissions as well as responding to various legislative challenges through the development of technical reports. She received a bachelor’s degree in chemistry and integrated arts from Northwestern University, US, and a master’s degree in biotechnology from Johns Hopkins University, US.

spacer
Matthew Weinberg
spacer
spacer
spacer
Emily Krulewitz
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Gyros Protein Technologies Appoints Frank Witney as Chairman

Automated nanoliter-scale immunoassays company today announced the appointment of a new Chairman of the Board
More info >>

White Papers

Faster, Better, Cheaper: Lean as a Driving Force Behind Pharmaceutical Companies’ Growth

TBM Consulting Group

The pharmaceutical industry faces countless challenges: patent expirations, weak product development pipelines, downward pricing pressure and an increasingly burdensome regulatory environment. The most important question for companies is now “How can we position ourselves optimally to be successful in the long term?” Some pharmaceutical companies used the economic downturn in 2009 to embrace measures in the fields of cost reduction and efficiency increases, which can be implemented at short notice. The continuous and consistent implementation of sustainable measures that guarantee stability and form the basis for future growth was not necessarily paramount within this.
More info >>

 
Industry Events

CPhI Worldwide 2017

24-26 October 2017, Messe Frankfurt, Germany

CPhI Worldwide, together with co-located events ICSE, InnoPack, P-MEC and FDF, hosts more than 42,000 visiting pharma professionals over three days. 2,500+ exhibitors from 153 countries gather at the event to network and take advantage of more than 150 free industry seminars. The exhibition covers every sector of the pharmaceutical market under one roof.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement